Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Damora Therapeutics, Inc.GLTO · Entity 4602 | Director | November 02, 2020 | November 04, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Damora Therapeutics, Inc.
Report date November 02, 2020 · Filed November 04, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 546,136 |
Last balance in matching sequence
After 2020-11-02 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2020-11-02 · Conversion · Acquired 479,470 · Balance 479,470 F3: The Series D Preferred Stock (the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date. F1: These shares are held by Eir Ventures I AB ("Eir Ventures"). F2: The Reporting Person is a founding partner of Eir Ventures Partners AB, the General Partner/Manager of Eir Ventures, and shares voting and dispositive power with respect to the shares held by Eir Ventures. Dr. Christgau disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein. Row 2 · 2020-11-02 · Purchase · Acquired 66,666 · Balance 546,136 F1: These shares are held by Eir Ventures I AB ("Eir Ventures"). F2: The Reporting Person is a founding partner of Eir Ventures Partners AB, the General Partner/Manager of Eir Ventures, and shares voting and dispositive power with respect to the shares held by Eir Ventures. Dr. Christgau disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein. |
| Series D Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-11-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-02 · Conversion · Disposed 184,433 · Balance 0 F3: The Series D Preferred Stock (the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date. F1: These shares are held by Eir Ventures I AB ("Eir Ventures"). F2: The Reporting Person is a founding partner of Eir Ventures Partners AB, the General Partner/Manager of Eir Ventures, and shares voting and dispositive power with respect to the shares held by Eir Ventures. Dr. Christgau disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are held by Eir Ventures I AB ("Eir Ventures").
F2: The Reporting Person is a founding partner of Eir Ventures Partners AB, the General Partner/Manager of Eir Ventures, and shares voting and dispositive power with respect to the shares held by Eir Ventures. Dr. Christgau disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein.
F3: The Series D Preferred Stock (the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 02, 2020 Filed Nov 4, 2020 20:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | ConversionSeries D Preferred Stock · Derivative | 184,433 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-030410 · doc4.xml · derivative · entry 3 Christgau Stephan · CIK 0001360578 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 479,470 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series D Preferred Stock (the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date. F3 · derivative.exercise_date: The Series D Preferred Stock (the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date. F3 · derivative.expiration_date: The Series D Preferred Stock (the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date. F1 · ownership.nature: These shares are held by Eir Ventures I AB ("Eir Ventures"). F2 · ownership.nature: The Reporting Person is a founding partner of Eir Ventures Partners AB, the General Partner/Manager of Eir Ventures, and shares voting and dispositive power with respect to the shares held by Eir Ventures. Dr. Christgau disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 20:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | PurchaseCommon Stock | 66,666 | $15.00 | $999,990.00 |
DisclosureSEC source: 0000899243-20-030410 · doc4.xml · nonDerivative · entry 2 Christgau Stephan · CIK 0001360578 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 546,136 F1 · ownership.nature: These shares are held by Eir Ventures I AB ("Eir Ventures"). F2 · ownership.nature: The Reporting Person is a founding partner of Eir Ventures Partners AB, the General Partner/Manager of Eir Ventures, and shares voting and dispositive power with respect to the shares held by Eir Ventures. Dr. Christgau disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 20:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | ConversionCommon Stock | 479,470 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030410 · doc4.xml · nonDerivative · entry 1 Christgau Stephan · CIK 0001360578 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 479,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The Series D Preferred Stock (the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date. F1 · ownership.nature: These shares are held by Eir Ventures I AB ("Eir Ventures"). F2 · ownership.nature: The Reporting Person is a founding partner of Eir Ventures Partners AB, the General Partner/Manager of Eir Ventures, and shares voting and dispositive power with respect to the shares held by Eir Ventures. Dr. Christgau disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.